Literature DB >> 8785400

Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group.

R P Sloan1, M M Schwartz, S M Korbet, R Z Borok.   

Abstract

The pathology of membranous glomerulonephritis (MGN) in patients with systemic lupus erythematosus (SLE) may be complicated by superimposed glomerular inflammation and/or necrosis. This retrospective study examined whether various histologic patterns of glomerulonephritis (GN) seen on renal biopsy impact upon the prognosis of these patients. Clinical parameters at the time of biopsy were also studied, to determine which might serve as risk factors associated with renal and patient outcome. On the basis of renal biopsy findings, patients were stratified into three pathological study groups by using the World Health Organization (WHO) classification (11). Thirty-six patients had "pure' SLE MGN without (WHO Va) or with (WHO Vb) mesangial hypercellularity. Fifteen patients had SLE MGN with segmental endocapillary proliferation and/or necrosis in < 50% of glomeruli (WHO Vc < 50%). Twenty-eight patients had SLE MGN with endocapillary proliferation and/or necrosis in > or = 50% of glomeruli (MGN with segmental proliferation and/or necrosis in > 50%, WHO Vc > or = 50%, or MGN with superimposed diffuse endocapillary proliferation, WHO Vd). There were no significant differences in sex, age, or race among patients in the three study groups. There was a trend for increasing serum creatinine concentration, urine protein excretion, and diastolic blood pressure, and decreasing the third component of serum complement (C3) to be associated with increasing glomerular inflammation, and these differences were significant when Vc > or = 50% and Vd was compared with Va and Vb (P < 0.05). The 5- and 10-yr actuarial survival rates without reaching the study outcomes of death or renal replacement therapy for the three study groups were 86, 72, and 49% and 72, 48, and 20% respectively, and the differences between Va and Vb and Vc > 50% and Vd were significant (P < 0.05). SLE MGN has a heterogeneous course and outcome, and this variability is related to the extent and degree of glomerulonephritis seen on renal biopsy. The only clinical factor with an independent risk of reaching a study outcome was elevation of the initial serum creatinine concentration (Cox regression analysis). This predictive value appears to apply only to patients with the most severe forms of glomerulonephritis, suggesting that they may have a different natural history and/or a response to therapy than SLE MGN with less widespread glomerular inflammation and/or necrosis.

Entities:  

Mesh:

Year:  1996        PMID: 8785400     DOI: 10.1681/ASN.V72299

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  22 in total

1.  Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria.

Authors:  Eduardo F Borba; Lissiane K Guedes; Romy B Christmann; Camille P Figueiredo; Célio R Gonçalves; Eloisa Bonfá
Journal:  Rheumatol Int       Date:  2006-05-31       Impact factor: 2.631

Review 2.  Recent advances in the treatment of lupus nephritis.

Authors:  Keiko Uchida; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2011-11-08       Impact factor: 2.801

3.  Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population.

Authors:  Juan Manuel Mejía-Vilet; Bertha M Córdova-Sánchez; Norma O Uribe-Uribe; Ricardo Correa-Rotter
Journal:  Clin Rheumatol       Date:  2016-07-30       Impact factor: 2.980

4.  ISN/RPS 2003 class II mesangial proliferative lupus nephritis: a comparison between cases that progressed to class III or IV and cases that did not.

Authors:  Seung Geun Lee; Yong Mee Cho; Min Wook So; Sung Soo Kim; Yong-Gil Kim; Chang-Keun Lee; Bin Yoo
Journal:  Rheumatol Int       Date:  2011-07-16       Impact factor: 2.631

5.  Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Authors:  Howard A Austin; Gabor G Illei; Michelle J Braun; James E Balow
Journal:  J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 10.121

6.  Lupus-like membranous nephropathy: Is it lupus or not?

Authors:  Ramin Sam; Amit Joshi; Sam James; Kuang-Yu Jen; Firouz Amani; Peter Hart; Melvin M Schwartz
Journal:  Clin Exp Nephrol       Date:  2014-07-04       Impact factor: 2.801

Review 7.  Membranous lupus nephritis in Chinese children--a case series and review of the literature.

Authors:  Sik-Nin Wong; Winnie Kwai-Yu Chan; Joannie Hui; Stella Chim; Tsz-Leung Lee; Kwok-Piu Lee; Lettie Chuk-Kwan Leung; Niko Kei-Chiu Tse; So-Fun Yuen
Journal:  Pediatr Nephrol       Date:  2009-07-22       Impact factor: 3.714

8.  Presentation and outcome of paediatric membranous non-proliferative lupus nephritis.

Authors:  Boris Hugle; Earl D Silverman; Pascal N Tyrrell; Elizabeth A Harvey; Diane Hébert; Susanne M Benseler
Journal:  Pediatr Nephrol       Date:  2014-07-31       Impact factor: 3.714

9.  Successful treatment of class V+IV lupus nephritis with multitarget therapy.

Authors:  Hao Bao; Zhi-Hong Liu; Hong-Lang Xie; Wei-Xin Hu; Hai-Tao Zhang; Lei-Shi Li
Journal:  J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 10.121

Review 10.  Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma.

Authors:  Chi Chiu Mok
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.